Walgreens in talks to go private

Amy Baxter | | Health Exec | Policy & Regulations
Some patients with certain autoimmune diseases in some states are finding it difficult to obtain their prescriptions for methotrexate as a result of changing abortion care laws.

Walgreens Boots Alliance is reportedly in talks to take the company private, according to CNBC. The deal would be the largest leveraged buyout in history, and the news comes after Walgreens announced it was closing 160 in-store clinics it owns and operates.

Walgreens is the nation’s second-largest pharmacy retail store chain. One of the reported firms looking at the buyout is KKR, which purchased Boots Alliance in 2007 and stayed an investor when Walgreens acquired Boots Alliance, CNBC reported. Walgreens currently has a market cap of $55 billion, with about $17 billion in debt.

Walgreens has experienced a stock slide over the last year, and its change in strategy for in-store clinics is part of cost-cutting measures. Its peers are also becoming larger, after CVS Health acquired health insurer Aetna last year. Walgreens shares rose on Nov. 5 after news of the potential deal broke.

See the full story below:

Walgreens explores going private in what could be largest LBO in history

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Report: 44% of adults in the U.S. are uninsured or underinsured
Texas AG sues hospital for $10K after off-duty police barred from carrying guns
Cardiologists reflect on developing primary PCI in face of criticism and pushback
PBMs sue FTC for alleged Fifth Amendment violation
FDA issues Class I alert on Philips ventilators after 4 injuries
Trump selects Emmy-winning TV personality Dr. Oz to head CMS

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”